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Background: Survivin is a member of Inhibitor of Apoptosis (IAP) 
family and considered to play a signiﬁcant role of tumorigenesis and 
proliferation. Over expression of survivin was reported in several can-
cers including non-small cell lung cancer (NSCLC), and these reports 
suggested there is correlation between survivin expression and patient’s 
prognosis. The purpose of this report is to clarify this relationship in 
NSCLC.
Methods: We examined 100 NSCLC tissues resected from 2000 Oct. 
to 2004 Dec. in Tohoku University Hospital. The 100 patients consisted 
of 71 men and 29 women. The median age was 66.2 (range 30-80). The 
histology and pathological staging were following: adenocarcinoma 71, 
squamous cell carcinoma 29, IA 35, IB 24, IIA 5, IIB 10, IIIA 16, IIIB 
9, IV 1. We assessed the expression of survivin, p53, NF kappa B, and 
Bcl-2 by immunohistochemistry. These proteins were considered to 
have correlation with survivin. Moreover mRNA expression of survivin 
variants was also examined by real time polymerase chain reaction 
(PCR). PCR primers were set for wild-type survivin, survivin-deltaEx3, 
survivin-2B, survivin-3B, and survivin-2alpha. 
Results: The number of cytoplasmic survivin-positive tissue was 88, 
and nuclear survivin-positive tissue was 40 (both positive was 36). We 
have 57 p53 positive, 67 NF kappa B positive, and 12 Bcl-2 positive 
tissues. The results for real time PCR will be reported.
Conclusions: We will analyse these data and show the relationship 
between expression of apoptosis related proteins including survivin and 
prognosis or stage. 
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Background: Our aim was to determine the genes predictive for re-
lapse-free and overall survival in stage I-II NSCLC. 
Methods: We analyzed the gene expression proﬁles in lung cancer 
specimens collected from 70 NSCLC patients (pts) who underwent 
curative pulmonary resection between 1999 and 2004. There were 54 
men and 16 women aged 37-77 yrs (median 62.5 yrs), 45 with squa-
mous cell ca, 22 with adenoca and 3 with large cell ca. Eight pts were 
staged pT1, 59 pT2 and 3 pT3; there were 49 and 21 pN0 and pN1 pts, 
respectively. 30 pts had a relapse and 32 pts died (median follow-up 36 
months). Samples of tumor tissue were collected intraoperatively and 
snap-frozen, total RNA was isolated and gene expression proﬁling was 
carried out by Affymetrix HG-U133 2.0 Plus oligonucleotide microar-
ray. Samples were pre-processed with RMA algorithm, gene selection 
was carried out by Support Vector Machines and Bayesian Compound 
Covariate Classiﬁer, using own procedures and BRB-Array software 
developed by Simon and Peng Lam. Survival time prediction was car-
ried out by method developed by Bair and Tibshirani (PLoS Biology 
2004).
Results: Based on the microarray gene expression proﬁling, the relapse 
could be predicted with 75% speciﬁcity and 53% sensitivity (positive 
predictive value [PPV] 62%, negative predictive value [NPV] 68%). 
The classiﬁer, obtained by cross-validation of 70-sample dataset, 
consisted of 170 transcripts. Further gene selection was based on the 
prediction of the relapse-free survival: 1919 genes, selected by ﬁtting 
Cox proportional hazard model (p<0.05) and further used to predict 
survival by 4 principal components, distinguished between pts with 
high and low risk of relapse (p<0.05, log-rank test). The prediction 
of death was possible with 66% speciﬁcity and 57% sensitivity (PPV 
53%, NPV 70%), but the distinction between high- and low-risk pts 
was signiﬁcantly weaker than based on lymph node involvement (N0 
vs. N1). Thus, for the ﬁnal selection of genes this clinical variable was 
incorporated into the model as a covariate. 
Conclusion: Prediction of the risk of relapse in stage I-II NSCLC 
based on the gene expression proﬁle is feasible, with NPV of 68%. 
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Purpose: Alterations in apoptosis-related proteins and DNA damage 
repair proteins are associated with resistance to chemotherapy or radio-
therapy, which is the most important cause of treatment failure in small 
cell lung cancer (SCLC). 
Patients and Methods: Pretreatment tumor biopsy specimens from 
77 patients with SCLC (limited stage: 40, extensive stage: 37) were 
analyzed for p53, bcl-2, bax and ERCC1 expression by immunohisto-
chemistry. All patients were treated with platinum-based doublets. The 
most commonly used regimen was etoposide/cisplatin (50 patients). In 
patients with limited stage SCLC, thoracic irradiation was performed 
either concurrently with chemotherapy or sequentially.
Results: High expression of p53, bcl-2, bax and ERCC1 was observed 
in 40 (52%), 72 (94%), 38 (49%) and 13 (17%) patients, respectively. 
High expression of ERCC1 was associated with poor OS (1-year, 23% 
vs. 53%; p=0.026). A signiﬁcant correlation between high expression of 
ERCC1 and poor outcome was observed only in patients with limited 
stage SCLC (p=0.017). High expression of p53, bcl-2 and bax was not 
correlated with patient outcome. Multivariate analysis showed that 
extensive stage (p=0.006) and male gender (p=0.009) were independent 
predictors of poor OS, while high expression of ERCC1 failed to reach 
statistical signiﬁcance despite a trend (p=0.057). In limited stage pa-
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tients, high expression of ERCC1 was an independent prognostic factor 
for poor OS (p=0.046), along with male gender (p=0.033).
Conclusion: High expression of ERCC1 protein may be a useful 
predictor of poor outcome in SCLC patients treated with chemotherapy 
with or without radiotherapy, especially in limited stage SCLC.
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Background: To investigate whether excision repair cross-complemen-
tation group 1 (ERCC1) expression as determined immunohistochemi-
cally, single nucleotide polymorphisms (SNPs) in the ERCC1 gene, 
and mutations of epidermal growth factor receptor (EGFR) are related 
to the prognosis of curatively resected non-small-cell lung cancer 
(NSCLC), and whether these markers are related.
Methods: One-hundred and thirty-three consecutive patients with 
NSCLC who did not receive adjuvant chemotherapy after curative 
surgery were included in this study. Representative areas from for-
malin-ﬁxed parafﬁn-embedded tumor samples were chosen for tissue 
microarray analysis. Immunohistochemistry was performed for ERCC1 
and the median semiquantitative H-score was used as a cut-off. EGFR 
mutations (exons 18, 19, and 21) were analyzed by the direct sequenc-
ing of tumor samples. Two SNPs in the ERCC1 gene, C8092A and 
T19007C, were investigated on the tumor samples.
Results: ERCC1 expression was evaluable in 130 patients and ERCC1 
was found to be positive in 80 patients (61.5%). Moreover, ERCC1 
was expressed more frequently in smokers and in squamous cell 
carcinomas. Patients with positive ERCC1 expression survived longer 
(median overall survival 2,742 days for ERCC1-positive vs. 1,423 
days for ERCC1-negative, P=.0463). EGFR mutations were found in 
27 patients (20.3%) but they were not found to affect overall survival. 
Interestingly, EGFR mutations were more frequent in ERCC1-negative 
tumors (12.5% in ERCC1-positive vs. 30% in ERCC1-negative tumors, 
P=.014). The SNPs in the ERCC1 gene were not associated with 
ERCC1 expression of the tumors and did not affect overall survival of 
the patients.
Conclusions: ERCC1 expression was identiﬁed as a prognostic marker 
of longer survival in resected NSCLCs. In addition, EGFR mutations 
were more frequently found in ERCC1-negative tumors, but were not 
found to affect survival in our patient group. 
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Background: Impaired signal transduction is associated with tumori-
genesis and progression of many kinds of human cancers. Transform-
ing growth factor (TGF)-beta/Smad and ras-mitogen activated protein 
kinase (MAPK) are two major signal transduction pathways for cells 
proliferation and differentiation, which transmit signals from the cell 
membrane to the nucleus. Activation of these two pathways may 
involve in malignant transformation. Although many researchers have 
assumed a role for deregulation of the Smads and MAPK pathways 
in the development of malignancy, only a few studies have looked at 
the Smad4 and MAPK activity in human lung cancers. Therefore, we 
detected the expression of Smad4, MAPK proteins (p38, ERK1/2 and 
JNK1) in NSCLC, and investigated their clinical signiﬁcance, espe-
cially with the prognosis. 
Methods: 71 primary non-small cell lung cancers (NSCLC) and paired 
lung normal tissues from the same patients were subject to investiga-
tion. These patients underwent surgery in 2001 and had been followed 
up for over 5 years. The expression of Smad4, p38, ERK1/2, JNK1 and 
their corresponding phosphorylated forms were detected using Western 
blot analysis of tissue homogenate from resected NSCLC and matched 
normal lung tissue. Immunohistochemical analysis was used to conﬁrm 
the cellular localization of the activated MAPKs and Smad4 in lung 
cancer cells. Using statistical analysis, we investigated the relationship 
among MAPKs, Smad4 and the clinicohistopathological factors, and 
their correlation with clinical prognosis.
Results: We found that only activated p38 (p-p38) was consistently 
increased in tumor compared with normal tissue, while Smad4 was 
signiﬁcantly decreased in lung cancer tissues than normal tissues (both 
p<0.05). Immunohistochemical analysis conﬁrmed the cellular localiza-
tion of the activated p38 in both the cytoplasm and nucleus, and Smad4 
in the nucleus only. Of various clinicohistopathological factors, the 
pathological staging (p-staging) was closely associated with the expres-
sion of p-p38 (P=0.000), p-ERK1/2(P=0.000), p-JNK1 (P=0.000) and 
Smad4 (P=0.005). Moreover, JNK1 is also correlated with the tumor 
location (P=0.028). The expression of Smad4 was inversely correlated 
with p-p38 (P=0.000) while no signiﬁcant correlation with ERK1/2 
and JNK1 (p=0.073, 0.451, respectively). Univariate analysis revealed 
worse prognosis in NSCLC patients with negative expression of 
Smad4, positive expression of p-p38 and p-JNK1 (P=0.0001, 0.0000, 
0.0208, respectively). And tumor differentiation and p-staging were 
signiﬁcantly correlated with the prognosis of NSCLC. While using 
multivariate analysis, only Smad4, p38, tumor differentiation and p-
staging were correlated with the prognosis (P=0.019, 0.044, 0.003, and 
0.020, respectively). Furthermore, the negative expression of p38 and 
positive expression of Smad4 were associated with a better prognosis 
of NSCLC, compared with the other combinations of p-p38 and Smad4 
(P=0.000). 
Conclusions: Therefore, we believe that Smad4 and p38 could be of 
importance in the signal transduction pathways for the initiation and 
development of NSCLC. Smad4 and p38 could be possibly used as 
prognostic factors for NSCLC. 
